Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study
Head & Neck · 2026-11-14
DOI: 10.1002/hed.70547 ↗At a glance
Journal article in Head & Neck, published online on 2026-11-14. Written by Phoebe L Sault and 3 co-authors. Institution: Sydney Pharmacy School, The University of Sydney, Camperdown, New South Wales, Australia. 63 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited.
Methods
A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index mortality data for patients initiating nivolumab monotherapy during 2019–2023. Overall survival (OS), time to treatment discontinuation (TTD), and dispensing‐based proxies for potential immune‐related adverse events (irAEs) were assessed.
Results
Among 1398 patients, median OS was 9.3 months and TTD was 7.8 months. Median OS was longer in males than females (10.0 vs. 7.7 months, p = 0.049), while patients with prior corticosteroid exposure had shorter OS than those without (8.3 vs. 11.5 months; aHR 1.20, 95% CI: 1.06–1.36). Incident corticosteroid and levothyroxine use occurred in 10.3% and 10.9% of patients, respectively.
Conclusions
Real‐world outcomes were comparable to clinical trial findings, supporting nivolumab's effectiveness in Australian clinical practice.
Subjects
Author keywords
Authors and institutions
- Sydney Pharmacy School, The University of Sydney, Camperdown, New South Wales, Australia.
- Real-World Precision Medicines Research Group, Kolling Institute, Faculty of Medicine and Health, The University of Sydney and the Northern Sydney Local Health District, Sydney, New South Wales, Australia.
- Pharmaceutical Policy Node, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Pharmacy, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, Australia.
ORCID profiles: Phoebe L Sault, Chin Hang Yiu, Edwin C K Tan, Christine Y Lu
Cite
APA
Sault, P. L., Yiu, C. H., Tan, E. C. K., & Lu, C. Y. (2026). Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study. Head & Neck. https://doi.org/10.1002/hed.70547
Vancouver
Sault PL, Yiu CH, Tan ECK, Lu CY. Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study. Head & Neck. 2026. doi:10.1002/hed.70547
BibTeX
@article{Sault2026,
author = {Sault, Phoebe L and Yiu, Chin Hang and Tan, Edwin C K and Lu, Christine Y},
title = {Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70547}
}
EUVIMED